NEW YORK (TheStreet) -- IsoRay (ISR) rose Monday after the medical technology company announced it had received final approval from the State of Washington Department of Health to manufacture its Liquid Cesium-131, or Cesitrex.
The U.S. Food and Drug Administration recently approved Liquid Cesium-131 to use with GliaSite balloon catheters to treat metastatic and glioblastoma brain cancers.
"Management believes this combination will offer a number of advantages in treating these debilitating brain cancers," the company said in a statement. "Liquid Cesium-131 eliminates the need for a thyroid block as required with Iodine-125, is safer for the patient and staff, and if a spill were to occur, it is an easier cleanup than with other isotopes."
Must Read: Warren Buffett's 10 Favorite Growth Stocks
The stock was up 10.87% to $2.55 at 11:02 a.m.